Auraptene

Auraptene is an orally active geranyloxycoumarin that can be isolated from plants in the Brassicaceae family, antibacterial, anti-pathogen, antioxidant, anti-tumor, and neuroprotective effects. Auraptene plays an important role in the treatment of various chronic diseases such as hypertension and cystic fibrosis^[1][2].
In Vitro:Auraptene (0-20 μM, 2 h) reduces the secretion of inflammatory mediators stimulated by lipopolysaccharides in oral epithelial cells and promotes wound healing by promoting cell migration^[1].
Auraptene (10 μM, 24 h) inhibits the cell cycle progression of human breast cancer cell line MCF-7 by reducing the expression of cyclin D1 protein and inhibiting IGF-1^[2].
Auraptene (10 μM, 4 days) exhibits antiviral activity against human coronavirus OC43 in MRC-5 cells^[6].
Auraptene (25-400 μM) protects red blood cells from free radical induced damage by preventing the consumption of intracellular antioxidant GSH and inhibiting protein peroxidation^[7].
In Vivo:Auraptene (200, 500 ppm, mixed in the diet, p.o.) delays the tumor progression of breast cancer rats by inhibiting cyclin D1 protein^[3].
Auraptene (100, 500 ppm, mixed in the diet, p.o.) alleviates gastritis by reducing Helicobacter pylori colonization and pro-inflammatory mediator production in C57BL/6 mice^[4].
Auraptene (5, 50 mg/kg, 6 weeks, p.o.) prevents heart failure caused by myocardial infarction by activating peroxisome proliferator activated receptor alpha (PPAR alpha) in rats ^[5].
Auraptene (2, 4, 8, 16 mg/kg, 5 weeks, p.o.) exhibits anti hypertensive effects in hypertensive rats by reducing mean systolic blood pressure^[8].